Caption Management’s Arcus Biosciences RCUS Stock Holding History

Caption Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$648K	–	1982
2026 Q1	$648K	Sell	30,000 -51,400	-63%	-$1.11M	﹤0.01%	1142
2025 Q4	$1.94M	Buy	+81,400	New	+$1.66M	0.01%	846
2024 Q4	–	Sell	-30,000	Closed	-$459K	–	1773
2024 Q3	$459K	Sell	30,000 -30,000	-50%	-$473K	0.01%	940
2024 Q2	$914K	Buy	+60,000	New	+$968K	0.01%	687
2024 Q1	–	Sell	-50,000	Closed	-$955K	–	1606
2023 Q4	$955K	Buy	+50,000	New	+$799K	0.01%	816
2023 Q3	–	Sell	-30,000	Closed	-$609K	–	1500
2023 Q2	$609K	Sell	30,000 -50,000	-63%	-$952K	0.01%	779
2023 Q1	$1.46M	Buy	+80,000	New	+$1.53M	0.03%	537
2022 Q3	–	Sell	-381,400	Closed	-$9.66M	–	1787
2022 Q2	$9.66M	Buy	381,400 +358,900	+1,595%	+$8.79M	0.13%	197
2022 Q1	$710K	Buy	+22,500	New	+$754K	0.01%	1070

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Caption Management's RCUS Position: Q2 2026 in Review

Caption Management increased its Arcus Biosciences (RCUS) stake by 287% in Q2 2026, buying an estimated $1.14M and bringing the position to 62,000 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #920.

Caption Management first reported a position in RCUS in Q1 2022 and has held it in 9 quarters since. The position peaked at $18.3M in Q4 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Caption Management held 62,000 shares of Arcus Biosciences worth $1.91M as of Q2 2026.
Caption Management bought 45,967 Arcus Biosciences shares in Q2 2026, an estimated $1.14M.
Arcus Biosciences made up 0.01% of Caption Management's portfolio in Q2 2026, its #920 holding.
Caption Management first reported a position in Arcus Biosciences in Q1 2022 and has held it in 9 quarters since.
Caption Management's Arcus Biosciences position peaked at $18.3M in Q4 2025.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.